$0.82
+0.03 (+3.67%)
Open$0.79
Previous Close$0.79
Day High$0.82
Day Low$0.73
52W High$2.22
52W Low$0.55
Volume—
Avg Volume132.9K
Market Cap9.54M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+4,302.9% upside
Current
$0.82
$0.82
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 527.6K | 1.10M | 1.13M |
| Net Income | -23,262,351 | 89.2K | 117.7K |
| Profit Margin | -4,409.1% | 8.1% | 10.4% |
| EBITDA | -24,393,537 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |